Eliquis (apixaban) is one of the most commonly prescribed blood thinners in the United States, used to prevent or treat dangerous blood clots and to reduce stroke risk in people with atrial fibrillation. At the same time, medical and recreational cannabis use has expanded rapidly, creating an increasingly common question for patients and clinicians: Can marijuana, THC, or CBD interact with Eliquis and increase the risk of bleeding?
The short answer is that a clinically significant interaction is possible but not well established. Apixaban is affected by specific drug-metabolizing enzymes and transport proteins, and laboratory and human research shows that certain cannabinoids—particularly cannabidiol (CBD) at sufficiently high doses—can interfere with some of those same pathways. However, published clinical evidence directly documenting marijuana-related bleeding in patients taking Eliquis remains extremely limited. A 2023 systematic review of cannabinoid-anticoagulant interactions found that essentially all published clinical interaction reports involved warfarin rather than direct oral anticoagulants such as apixaban.
Why Drug Interactions Matter With Eliquis
Eliquis belongs to a class of medications known as direct oral anticoagulants, or DOACs. Apixaban blocks factor Xa, an important protein in the clotting cascade, thereby reducing the body’s ability to form blood clots. This can prevent strokes, deep-vein thrombosis and pulmonary embolism, but it also means that excessive apixaban exposure can increase the chance of unwanted bleeding. The current FDA prescribing information warns that Eliquis can cause serious or potentially fatal bleeding and notes that medications affecting its metabolism or hemostasis can substantially alter that risk.
Two pathways are particularly relevant when considering cannabis. Apixaban is a substrate of P-glycoprotein, or P-gp, a transporter involved in moving drugs across cell membranes, and it is partly metabolized by the liver enzyme CYP3A4. The 2023 American College of Cardiology / American Heart Association atrial fibrillation guideline therefore emphasizes screening patients taking DOACs for medications that inhibit or induce CYP3A4 or P-glycoprotein. Strong inhibition of these pathways can increase apixaban exposure, whereas strong induction can lower apixaban concentrations and potentially make anticoagulation less effective.
The interaction is not merely theoretical when powerful pharmaceutical inhibitors are involved. In a pharmacokinetic study, ketoconazole—a strong CYP3A4 and P-gp inhibitor—approximately doubled overall apixaban exposure. Diltiazem, a more moderate inhibitor, increased apixaban exposure by about 40 percent. These findings help explain why substances capable of interfering with the same pathways attract concern when they are combined with Eliquis.
How Cannabis Could Theoretically Affect Eliquis
Cannabis contains dozens of biologically active cannabinoids, but THC and CBD are the two most relevant to potential drug interactions. THC produces most of marijuana’s intoxicating effects, while CBD is generally non-intoxicating. They do not behave identically in the liver. Laboratory research has repeatedly demonstrated that CBD can inhibit several cytochrome P450 enzymes, including CYP3A enzymes under experimental conditions. One frequently cited human-liver-microsome study found that CBD inhibited CYP3A4 substantially more strongly than THC.
CBD has also demonstrated effects on P-glycoprotein in laboratory experiments. Researchers studying intestinal and transporter cell models found that sufficiently high CBD concentrations could inhibit P-gp-mediated transport, raising the theoretical possibility that CBD might increase exposure to drugs transported by P-gp. Because apixaban relies partly on both CYP3A4 and P-glycoprotein for its disposition, simultaneous interference with these systems could conceivably increase the amount of Eliquis circulating in the bloodstream.
That does not mean smoking marijuana or taking a small amount of CBD automatically raises Eliquis concentrations. Laboratory inhibition studies often use cannabinoid concentrations that may not reflect those produced by ordinary cannabis consumption. Drug interactions depend on cannabinoid dose, frequency, route of administration, formulation, liver function, kidney function and the other medications a person takes. The mechanism therefore provides a reason for caution rather than proof that a clinically important interaction occurs every time cannabis and apixaban are combined.
High-Dose CBD May Present More Interaction Potential Than THC
Modern human research has strengthened the evidence that high CBD exposure can alter the metabolism of certain drugs. In a randomized crossover study involving healthy adults, researchers administered a cannabis extract containing 640 mg CBD plus 20 mg THC and then measured several drugs used as probes for individual liver enzymes. The CBD-rich preparation increased exposure to midazolam, a CYP3A substrate, by approximately 56 percent. By contrast, a preparation containing 20 mg THC without CBD did not significantly inhibit any of the CYP pathways tested.
This does not prove that CBD increases Eliquis concentrations by 56 percent. Midazolam and apixaban are different drugs, and apixaban has multiple elimination pathways. Still, the study is important because it confirms in humans that a sufficiently large oral CBD dose can inhibit CYP3A activity. Pharmaceutical CBD provides additional evidence that substantial cannabinoid doses can cause clinically meaningful drug interactions. The FDA-approved CBD medication Epidiolex, for example, increased exposure to everolimus—another drug affected by CYP3A4 and P-gp—by approximately 2.5-fold in a controlled interaction study.
Dose is crucial when interpreting these findings. The 640-mg CBD dose used in the CYP study is far higher than the amount contained in many recreational cannabis products, while prescription Epidiolex is administered at doses that can reach hundreds of milligrams per day. Someone taking a low-CBD cannabis flower occasionally is therefore not experiencing the same exposure as a patient consuming several hundred milligrams of oral CBD. Nevertheless, concentrated CBD oils, tinctures, capsules and high-dose edibles can sometimes deliver substantially larger CBD doses than consumers realize, making the distinction clinically relevant.
What Clinical Evidence Actually Shows
Despite the plausible mechanism, researchers have not established a clear real-world Eliquis-cannabis interaction. A systematic review published in Pharmacotherapy in 2023 searched hundreds of publications examining cannabinoids and anticoagulants. The investigators found seven reports suggesting an interaction between cannabis or cannabinoids and warfarin, but essentially no clinical evidence demonstrating an interaction with direct oral anticoagulants such as apixaban. Most warfarin cases involved elevated INR values, indicating increased anticoagulant effect.
Warfarin is importantly different from Eliquis. Its anticoagulant activity is strongly influenced by CYP2C9 and several other metabolic pathways, and its effect is routinely measured using the international normalized ratio, or INR. Apixaban does not require routine INR testing, which makes subtle pharmacokinetic interactions harder to identify in everyday clinical practice. The absence of published Eliquis case reports therefore does not necessarily prove that no interaction exists; it means researchers currently lack direct evidence showing how frequently the combination causes clinically meaningful changes.
A separate review of cannabinoids and oral anticoagulants reached essentially the same conclusion. Reports involving CBD and cannabis had raised concerns with warfarin, but there were no published clinical interaction studies involving CBD and DOACs at the time of the review. The authors emphasized the need for direct pharmacokinetic research rather than extrapolating automatically from laboratory studies.
Do THC and Marijuana Smoke Carry the Same Risk as CBD?
THC appears less likely than large doses of CBD to produce a major CYP3A4 interaction based on currently available research. In the controlled human cannabinoid interaction study, 20 mg of oral THC alone did not significantly inhibit the enzymes examined, including CYP3A. Laboratory studies likewise generally show weaker CYP3A4 inhibition from THC than from CBD. That makes the potential pharmacokinetic concern particularly relevant to CBD-rich products and high oral CBD doses, rather than allowing a blanket statement that all marijuana substantially increases Eliquis levels.
THC can nevertheless create other problems for someone receiving anticoagulation. Cannabis can impair reaction time, coordination, judgment and movement. The CDC notes that recent cannabis exposure can affect coordination and decision-making, particularly with THC-containing products. For a person taking a medication that increases bleeding risk, an intoxication-related fall, head injury or accident can carry greater consequences because internal bleeding may be harder to stop.
Smoking also introduces a complicated mixture of combustion products that is fundamentally different from taking purified CBD orally. Research has not established that smoking marijuana produces a predictable increase in apixaban concentrations. As a result, it is more accurate to evaluate cannabis according to cannabinoid composition, dose and method of use rather than assuming that marijuana flower, THC edibles and concentrated CBD oils have equivalent interaction risks.
Other Factors Can Increase the Bleeding Risk
Cannabis is only one part of the equation. The FDA warns that Eliquis itself increases bleeding risk and that combining it with other medications affecting clotting can make bleeding more likely. These include aspirin, other antiplatelet medications, heparin, other anticoagulants, nonsteroidal anti-inflammatory drugs such as ibuprofen and naproxen, and certain antidepressants including SSRIs and SNRIs.
Age, kidney function, liver disease and body weight can also influence apixaban exposure. The ACC/AHA guideline notes that renal function, hepatic function, age, weight and interacting medications should all be considered when selecting and dosing a DOAC. Someone taking Eliquis along with several medications that inhibit CYP3A4 or P-gp could therefore have a different risk profile from an otherwise healthy person taking the same Eliquis dose.
Clinical anticoagulation guidance reflects this cumulative approach. The American Society of Hematology advises clinicians to consider concomitant medications affecting P-glycoprotein or CYP3A4 when selecting anticoagulants. Likewise, the European Heart Rhythm Association recommends increased caution when multiple drug-interaction or bleeding-risk factors occur together rather than evaluating every substance in isolation.
CBD Products Add Another Layer of Uncertainty
Commercial CBD products create a special problem because consumers may not always know precisely how much CBD—or THC—they are taking. Unlike prescription Epidiolex, most over-the-counter CBD oils, gummies and tinctures have not gone through the FDA drug-approval process. The FDA warns specifically that CBD can affect the way other medications work and that unapproved products have not been evaluated to determine appropriate doses or the full range of potential drug interactions.
This uncertainty matters more with narrow-margin therapies such as anticoagulation. A label reading “CBD” does not necessarily tell a clinician how much cannabidiol reaches the bloodstream. Oral CBD undergoes substantial first-pass metabolism, food can influence absorption, and cannabinoid concentrations vary enormously among formulations. Occasional use of a low-dose product and daily use of a concentrated CBD tincture should therefore not automatically be placed in the same risk category.
The FDA’s prescription-CBD data also demonstrate why CBD should not be considered pharmacologically inactive simply because it does not produce a traditional marijuana high. CBD has documented effects on drug metabolism, can alter exposure to certain medications and has been associated with liver-enzyme elevations at substantial doses. The FDA consequently recommends discussing CBD use with a healthcare professional when other medications are involved.
Warning Signs of Excessive Anticoagulation or Bleeding
Someone taking Eliquis should already be alert for unusual bleeding regardless of cannabis use. Concerning symptoms include persistent or unexplained bleeding, unusually frequent nosebleeds, significantly increased bruising, red or brown urine, black or bloody stools, vomiting or coughing blood, or unexpectedly heavy menstrual bleeding. Sudden severe headache, weakness, dizziness, confusion or neurological symptoms after a fall or head injury can be especially important because intracranial bleeding may not always be externally visible. The Eliquis medication guide instructs patients to obtain medical care promptly when significant bleeding symptoms develop.
The risk does not justify stopping Eliquis without medical direction. The FDA prescribing information carries a boxed warning that prematurely discontinuing apixaban without adequate alternative anticoagulation increases the risk of thrombotic events. For someone receiving Eliquis because of atrial fibrillation, a previous clot or another high-risk condition, abruptly stopping treatment could increase the risk of stroke, deep-vein thrombosis or pulmonary embolism.
For the same reason, people should not simply cut Eliquis tablets, skip doses or reduce their prescribed dose because they plan to use cannabis. FDA dosing changes involving interacting medications are based on specific known inhibitors and clinical circumstances. Cannabis has not been studied sufficiently to support a standardized “marijuana-adjusted” apixaban dose.
Can You Use Cannabis While Taking Eliquis?
Current evidence does not support saying that cannabis is universally contraindicated with Eliquis, but neither does it justify declaring the combination completely interaction-free. High-dose CBD deserves the greatest pharmacokinetic caution because human and laboratory studies show that CBD can alter metabolic pathways relevant to apixaban. THC-dominant products appear less likely to strongly inhibit CYP3A4 at typical exposures, although they can introduce impairment, falls and other indirect risks that matter more when someone is anticoagulated.
People who use cannabis regularly should make sure the clinician prescribing their anticoagulant knows what they use, including CBD oils, gummies, medical cannabis products and other cannabinoid preparations. The approximate THC and CBD content, frequency of use and route of administration can all matter. A pharmacist can also review the entire medication list for additional CYP3A4, P-gp or bleeding-related interactions rather than evaluating marijuana in isolation.
This becomes especially important when someone starts using a high-dose CBD product, dramatically increases cannabis consumption, develops kidney or liver disease, or begins another medication known to interact with apixaban. The goal is not necessarily to prohibit cannabis use but to prevent an avoidable combination of risk factors.
The Bottom Line on Cannabis and Eliquis
There is a plausible biological mechanism through which cannabis—especially large doses of CBD—could affect Eliquis. Apixaban is influenced by CYP3A4 and P-glycoprotein, while laboratory studies and controlled human research show that CBD can inhibit CYP3A activity and affect drug transport or exposure under certain conditions. Pharmaceutical-grade CBD has also demonstrated meaningful interactions with some CYP3A4/P-gp substrates.
What researchers do not currently have is strong clinical evidence showing that ordinary marijuana use reliably raises apixaban concentrations or causes excess bleeding in people taking Eliquis. The most comprehensive anticoagulant review found clinical cannabinoid interactions primarily with warfarin, highlighting a significant evidence gap for apixaban and other DOACs.
For now, the most accurate conclusion is therefore neither “marijuana is safe with Eliquis” nor “marijuana and Eliquis can never be combined.” The evidence supports caution, disclosure and individualized assessment, with particular attention to concentrated or high-dose CBD products and other medications that increase bleeding or interfere with CYP3A4 and P-glycoprotein. Until direct apixaban-cannabis interaction trials are performed, clinicians and patients have to work from known apixaban pharmacology, cannabinoid interaction research and the individual’s overall bleeding risk rather than a definitive cannabis-specific dosing rule.
